#investor-vetting

#investor-vetting

Some financial experts recommend enjoying a portion of the windfall while allocating the rest towards savings or investments to ensure long-term benefits.

Launching a fund used to be a real test of endurance, with timelines often stretching across many months. The process demanded patience that many ambitious founders found difficult to sustain.

For most companies, there's roughly a 12-month period where the business is at its peak value, and then it crashes out. The companies that capture generational returns are often the ones where someone spies that moment instead of assuming the good times will get even better.

Polymarket is reportedly in advanced talks to raise approximately $400 million in new funding at a post-money valuation of roughly $15 billion, according to a report published by The Information. The round has not been finalized, meaning terms could still change.

Cursor is nearing a funding round of at least $2 billion, with returning investors Thrive and Andreessen Horowitz expected to lead the financing at a $50 billion valuation. The deal terms are not final and may still change.

Awards may be encouraging and occasionally useful for visibility, but they are weak indicators of validation and poor predictors of long-term success. In the longevity and healthspan industry, where timelines are long and claims are easy to overstate, venture capital ultimately follows alignment and evidence, not applause received at glitzy industry events.